Caledonia Investments plc Banner Image

Caledonia Investments plc

  • Ticker CLDN
    Exchange LSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Caledonia Investments plc Logo Image
  • 51-200 Employees
  • Based in London, England
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heartMore. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.
4.8 / 5.0 (82)

Caledonia Investments plc reports have an aggregate usefulness score of 4.8 based on 82 reviews.

Caledonia Investments plc

Most Recent Annual Report

Caledonia Investments plc
MOST RECENT 2023 Annual Report

Caledonia Investments plc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Caledonia Investments plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!